Growth-Related Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Growth-Related Disorders Home
    • Products
      Treatments
    • Professional Resources
      Product Resources Library Contact Your Representative Growth Calculators
    • Disease Education
      Pediatric Growth-Related Disorders (Basics) Adult Growth Hormone Deficiency
    • Treatment Guidelines
      PES & AACE Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Advocacy & Support Groups Disease Education Resources
    • Access & Affordability
      Insurance Support & Prescription Savings ICD-10 Codes for Growth-Related Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, 15 mg logo
Important Safety Information | Patient Site
Prescribing Information
  • The Need for Once-Weekly
    • How It Works
    • Sogroya® Pen
    • Device Attribute Chart
    • Patient Profiles
    • Pediatric Growth Hormone Deficiency
    • Adult Growth Hormone Deficiency
    • IGF-1 Response
    • Pediatric Dosing
    • Adult Dosing
    • Administration
    • Pen Selector
    • Patient Support
    • Formulary Coverage
    • Patient Materials
    • Provider Materials
    • Clinical Education
    • FAQ
Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, 15 mg logo

Sogroya® is indicated for pediatric patients aged 2.5 years and older with growth failure due to inadequate secretion of endogenous growth hormone (GH), and for replacement of endogenous GH in adults with growth hormone deficiency (GHD).

Prescribing Information
Important Safety Information | Patient Site

WHY A ONCE-WEEKLY THERAPY?

WHY A ONCE-WEEKLY THERAPY?

Understand how growth hormone deficiency (GHD) can affect pediatric and adult patients.

Understand how growth hormone deficiency (GHD) can affect pediatric and adult patients.

Patients with GHD continue to face challenges with daily injections1

Daily injections may present obstacles for patients and caregivers

Calendar with crossed out days and pen icon

Non-adherence to daily GH treatment is common and has been addressed in many studies2,3

Arrows with pen and exclamation mark icon

Repeated injections are one of the main causes of non-adherence in pediatric-aged patients4

Pen with sad face icon

Children, adolescents, and their caregivers may struggle with continual daily injections over the long term1

GH=growth hormone; GHD=growth hormone deficiency

Missing

1 DAY

per week of daily
GH treatment

White arrow pointing down
White arrow pointing right

results in missing up to

52 DAYS

of treatment
in a year

White arrow pointing down
White arrow pointing right

which equates to missing

~1 YEAR

of doses over a 7-year
treatment period

In a systematic literature review and meta-analysis of medication adherence with once-weekly vs once-daily therapy,

Once-weekly treatment adherence was ~2X better than once‑daily treatment5,a


According to an LAGH Consensus Statement for pediatric GHD patients, developed independently by a panel of renowned pediatric endocrinology experts6:

  • LAGH formulations offer a potential advantage over daily GH injections for children with GH deficiency in terms of reduced injection frequency and treatment burden; this may also be associated with improved adherence and treatment outcomes over time. However, long-term data is needed
  • Parents/caregivers have shown a strong preference for the reduced frequency of LAGH preparations over daily GH formulations
  • It is likely that most if not all children could be considered for a weekly administration regimen, particularly children or their caregivers who experience challenges with injections, as well as those at increased risk of non-adherence, frequent travel schedules, and split households

Consider if the flexibility of a once-weekly GH treatment option may impact your patient’s persistence and treatment experience

aMeta-analysis of observational studies which were conducted in patients with osteoporosis.5

GH=growth hormone; GHD=growth hormone deficiency; LAGH=long-acting growth hormone.

GHD occurs in adults and has associated symptoms and conditions

Adult GHD (AGHD) is most often acquired from7,8:

Brain Icon

A pituitary tumor7,8

Including treatment with surgery and/or radiation8

Brain Icon with lightning bolt

Trauma to the brain7

Other patient subpopulations include subarachnoid hemorrhage, ischemic stroke, and infections in the central nervous system7

AGHD may also be idiopathic or due to other organic causes.7,8

Symptoms and associated conditions of adult GHD include7:

Head icon with battery inside

Reduced energy levels

Arm flexed icon

Reduced muscle strength

Knee Flexed icon

Osteoporosis

Blood Drop icon

Lipid abnormalities

Scale Icon

Increased total body fat

Sogroya® pen icon

Insulin resistance

Heart Icon

Impaired cardiac function

Symptoms and associated conditions of adult GHD include7:

Head with battery icon

Reduced energy levels

Arm muscle icon

Reduced muscle strength

Spine and pelvis icon

Osteoporosis

Blood drops icon

Lipid abnormalities

Person growing icon

Increased total body fat

Injection pen icon

Insulin resistance

Heart pumping icon

Impaired cardiac function

Management of adult GHD

Per the American Association of Clinical Endocrinologists (AACE), identifying adult patients with GHD includes assessing8:

File icon

PATIENTS WITH CLINICAL FEATURES SUGGESTIVE OF AGHD

Patients with clinical features suggestive of AGHD, eg, patients with organic hypothalamic-pituitary disease and low-serum IGF-1 levels

PATIENTS WITH CLINICAL FEATURES SUGGESTIVE OF AGHD

eg, patients with organic hypothalamic-pituitary disease and low-serum IGF-1 levels


DNA icon

BIOCHEMICALLY PROVEN EVIDENCE OF AGHD

eg, GH stimulation testing

BIOCHEMICALLY PROVEN
EVIDENCE OF AGHD

eg, GH stimulation testing

Treatment options1,8

  • With diagnosis confirmed, AACE recommends treating AGHD with growth hormone therapy8
  • While once-daily GH treatment is considered the standard of care, according to GRS consensus, a once-weekly GH option may also help1

AGHD=adult growth hormone deficiency; GH=growth hormone; GHD=growth hormone deficiency; GRS=Growth Hormone Research Society; IGF-1=insulin-like growth factor-1.

Discover the pen

Discover the pen

Take a look at the features of the Sogroya® pen.

Explore the pen
Injection pen icon

Take a look at the features of the Sogroya® pen.

Explore the pen

How does it work?

How does it work?

Discover the science behind Sogroya®.

See how it works
Molecule icon

Discover the science behind Sogroya®.

See how it works

Important Safety Information for Sogroya®

Contraindications

Sogroya® is contraindicated in patients with:

  • acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya®
  • hypersensitivity to Sogroya® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin
  • pediatric patients with closed epiphyses
  • active malignancy
  • active proliferative or severe non-proliferative diabetic retinopathy
  • pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death

Warnings & Precautions

  • Increased Mortality in Patients with Acute Critical Illness: Increased mortality has been reported after treatment with somatropin in patients with acute critical illness due to complications following open-heart surgery, abdominal surgery, multiple accidental trauma, and in patients with acute respiratory failure

Indications and Usage

Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg is indicated for the:

  • treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH)
  • replacement of endogenous GH in adults with growth hormone deficiency (GHD)

Important Safety Information

Contraindications

Sogroya® is contraindicated in patients with:

  • acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure because of the risk of increased mortality with use of Sogroya®
  • hypersensitivity to Sogroya® or any of its excipients. Systemic hypersensitivity reactions have been reported postmarketing with somatropin
  • pediatric patients with closed epiphyses
  • active malignancy
  • active proliferative or severe non-proliferative diabetic retinopathy
  • pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to risk of sudden death

Warnings & Precautions

  • Increased Mortality in Patients with Acute Critical Illness: Increased mortality has been reported after treatment with somatropin in patients with acute critical illness due to complications following open-heart surgery, abdominal surgery, multiple accidental trauma, and in patients with acute respiratory failure
  • Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported postmarketing with use of somatropin. Inform patients and/or caregivers that such reactions are possible, and that prompt medical attention should be sought if an allergic reaction occurs
  • Increased Risk of Neoplasms: There is an increased risk of malignancy progression with somatropin in patients with active malignancy. Any preexisting malignancy should be inactive, and its treatment complete prior to instituting Sogroya®. In childhood cancer survivors treated with radiation to the brain/head for their first neoplasm who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Monitor patients with a history of GHD secondary to an intracranial neoplasm for progression or recurrence of the tumor. Children with certain rare genetic causes of short stature have an increased risk of developing malignancies and should be carefully monitored for development of neoplasms. Monitor patients for increased growth or potential malignant changes of preexisting nevi. Advise patients/caregivers to report changes in the appearance of preexisting nevi
  • Glucose Intolerance and Diabetes Mellitus: Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses. New onset type 2 diabetes has been reported. Monitor glucose levels in all patients, especially in those with existing diabetes mellitus or with risk factors for diabetes mellitus, such as obesity, Turner syndrome or a family history of diabetes mellitus. The doses of antidiabetic agents may require adjustment when Sogroya® is initiated
  • Intracranial Hypertension: Has been reported usually within 8 weeks of treatment initiation. Perform fundoscopic examination prior to initiation of treatment and periodically thereafter. If papilledema is identified, evaluate the etiology, and treat the underlying cause before initiating Sogroya®. If papilledema is observed, stop treatment. If intracranial hypertension is confirmed, Sogroya® can be restarted at a lower dose after intracranial hypertension signs and symptoms have resolved
  • Fluid retention: May occur during Sogroya® therapy. Clinical manifestations of fluid retention (e.g. edema and nerve compression syndromes including carpal tunnel syndrome/paresthesia) are usually transient and dose dependent
  • Hypoadrenalism: Patients receiving somatropin therapy who have or are at risk for corticotropin deficiency may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya®. Monitor patients with known hypoadrenalism for reduced serum cortisol levels and/or need for glucocorticoid dose increases
  • Hypothyroidism: Undiagnosed/untreated hypothyroidism may prevent an optimal response to Sogroya®. Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of Sogroya®
  • Slipped Capital Femoral Epiphysis in Pediatric Patients: Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Evaluate pediatric patients with the onset of a limp or complaints of persistent hip or knee pain
  • Progression of Preexisting Scoliosis in Pediatric Patients: Monitor patients with a history of scoliosis for disease progression
  • Pancreatitis: Cases of pancreatitis have been reported in patients receiving somatropin. The risk may be greater in pediatric patients compared to adults. Consider pancreatitis in patients with persistent severe abdominal pain
  • Lipohypertrophy/Lipoatrophy: May occur if Sogroya® is administered at the same site over a long period of time. Rotate injection sites to reduce this risk
  • Sudden death in Pediatric Patients with Prader-Willi Syndrome: There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Sogroya® is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome
  • Laboratory Tests: Serum levels of inorganic phosphorus and alkaline phosphatase may increase after Sogroya® therapy. Serum levels of parathyroid hormone may increase with somatropin treatment

Adverse Reactions

  • Pediatric patients with GHD: Adverse reactions reported in ≥5% of patients are nasopharyngitis, headache, pyrexia, pain in extremity, and injection site reaction
  • Adult patients with GHD: Adverse reactions reported in >2% of patients are back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, and anemia

Drug Interactions

  • Glucocorticoids: Patients treated with glucocorticoid for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Sogroya®
  • Cytochrome P450-Metabolized Drugs: Sogroya® may alter the clearance. Monitor carefully if used with Sogroya®
  • Oral Estrogen: Patients receiving oral estrogen replacement may require higher Sogroya® dosages
  • Insulin and/or Other Antihyperglycemic Agents: Dose adjustment of insulin and/or antihyperglycemic agent may be required for patients with diabetes mellitus

Please click here for Sogroya® Prescribing Information.

References:

  1. Christiansen JS, Backeljauw PF, Bidlingmaier M, et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174(6):C1–C8. doi:10.1530/EJE-16-0111
  2. Graham S, Weinman J, Auyeung V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr. 2018;90(4):221-227. doi:10.1159/000493211
  3. Bagnasco F, Di Iorgi N, Roveda A, Gallizia A, Haupt R, Maghnie M; Adherence Investigators Group. Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study. Endocr Pract. 2017;23(8):929-941. doi:10.4158/EP171786.OR
  4. Mameli C, Orso M, Calcaterra V, et al. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: a systematic review and meta-analysis. Pharmacol Res. 2023;193:106805. doi:10.1016/j.phrs/2023.106805
  5. Iglay K, Cao X, Mavros P, Joshi K, Yu S, Tuncell K. Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy. Clin Ther. 2015;37(8):1813-1821.e1. doi:10.1016/j.clinthera.2015.05.505
  6. Maniatis A, Cutfield W, Dattani M, et al. Long-acting growth hormone therapy in pediatric growth hormone deficiency: a consensus statement. J Clin Endocrinol Metab. Published online December 3, 2024. doi:10.1210/clinem/dgae834
  7. National Organization for Rare Disorders (NORD). Growth hormone deficiency. Updated 2016. Accessed November 17, 2022. https://rarediseases.org/rare-diseases/growth-hormone- deficiency
  8. Yuen KCJ, Beverly MKB, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract. 2019;25(11):1191-1232.
Growth-Related Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Growth-Related Disorders Home
  • Product Information
    Products
    • Treatments
    Professional Resources
    • Product Resources Library
      Contact Your Representative
      Growth Calculators
  • Professional Education
    Disease Education
    • Pediatric Growth-Related Disorders (Basics)
      Adult Growth Hormone Deficiency
    Treatment Guidelines
    • PES & AACE Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Advocacy & Support Groups
      Disease Education Resources
    Access & Affordability
    • Insurance Support & Prescription Savings
      ICD-10 Codes for Growth-Related Disorders

Sogroya® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2025 Novo Nordisk All rights reserved. US25SOM00002 May 2025

Quick links

Treatments

Insurance support & patient savings

Pediatric disorders overview

Clinical education for your patients